A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa

British Journal of Dermatology

Volumn 165, Issue 2, 2011, Pages 391-398

  Miller, I ^a   Lynggaard, C D ^a   Lophaven, S ^a   Zachariae, C ^b   Dufour, D N ^a   Jemec, G B E ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; PLACEBO;

ADULT; ARTICLE; ATRIOVENTRICULAR BLOCK; CHOLELITHIASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRY EYE; DRY SKIN; EAR DISEASE; EAR IRRITATION; FEMALE; GASTROINTESTINAL SYMPTOM; HAY FEVER; HEADACHE; HEMATOMA; HOARSENESS; HUMAN; HURLEY SCORING SYSTEM; INFECTION; MALE; MULTICENTER STUDY; MYALGIA; NECK INJURY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SARTORIUS SCORING SYSTEM; SCAR FORMATION; SCORING SYSTEM; SIDE EFFECT; SLEEP DISORDER; SUPPURATIVE HIDRADENITIS; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 79960622489     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10339.x     Document Type: Article

References (37)

1. Jemec GBE, Leyden JJ,. Hidradenitis Suppurativa. Berlin: Springer-Verlag, 2006.
2. Revuz J,. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009; 23: 985-98.
3. von der Werth JM, Jemec GB,. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 2001; 144: 809-13. (Pubitemid 32374785)
4. Wolkenstein P, Loundou A, Barrau K, et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007; 56: 621-3. (Pubitemid 46400178)
5. Jemec GB, Heidenheim M, Nielsen NH,. A case-control study of hidradenitis suppurativa in an STD population. Acta Derm Venereol (Stockh) 1996; 76: 482-3. (Pubitemid 26398101)
6. Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59: 596-601.
7. von Laffert M, Helmbold P, Wohlrab J, et al. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol 2010; 19: 533-7.
8. Jemec GB, Hansen U,. Histology of hidradenitis suppurativa. J Am Acad Dermatol 1996; 34: 994-9. (Pubitemid 26170764)
9. Yu CC, Cook MG,. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 1990; 122: 763-9. (Pubitemid 20182193)
10. Kurzen H, Kurokawa I, Jemec GB, et al. What causes hidradenitis suppurativa? Exp Dermatol 2008; 17: 455-6.
11. Dufour DN, Bryld LE, Jemec GB,. Hidradenitis suppurativa complicating naevus comedonicus: the possible influence of mechanical stress on the development of hidradenitis suppurativa. Dermatology 2010; 220: 323-5.
12. Boer J, Weltevreden EF,. Hidradenitis suppurativa or acne inversa. A clinicopathological study of early lesions. Br J Dermatol 1996; 135: 721-5. (Pubitemid 26375888)
13. Hunger RE, Surovy AM, Hassan AS, et al. Toll-like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C-type lectin receptor. Br J Dermatol 2008; 158: 691-7. (Pubitemid 351415729)
14. Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C, et al. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol 2007; 156: 51-6. (Pubitemid 44924144)
15. Jemec GB,. Medical treatment of hidradenitis suppurativa. Expert Opin Pharmacother 2004; 5: 1767-70. (Pubitemid 39117719)
16. Clemmensen OJ,. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 1983; 22: 325-8. (Pubitemid 13107515)
17. Jemec GB, Wendelboe P,. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 1998; 39: 971-4. (Pubitemid 28547731)
18. van der Zee HH, Boer J, Prens EP, Jemec GB,. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology 2009; 219: 143-7.
19. Gener G, Canoui-Poitrine F, Revuz JE, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology 2009; 219: 148-54.
20. Lapins J, Sartorius K, Emtestam L,. Scanner-assisted carbon dioxide laser surgery: a retrospective follow-up study of patients with hidradenitis suppurativa. J Am Acad Dermatol 2002; 47: 280-5.
21. 2 laser stripping-secondary intention technique. Br J Dermatol 1994; 131: 551-6. (Pubitemid 24315426)
22. Rompel R, Petres J,. Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg 2000; 26: 638-43. (Pubitemid 30470626)
23. van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol 2011; 164: 1292-8.
24. Haslund P, Lee RA, Jemec GB,. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol (Stockh) 2009; 89: 595-600.
25. Lee RA, Dommasch E, Treat J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2009; 60: 565-73.
26. Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010; 62: 205-17.
27. Sartorius K, Lapins J, Emtestam L, Jemec GB,. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol 2003; 149: 211-13. (Pubitemid 36966545)
28. Hurley HJ,. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus: surgical approach. In: Dermatologic Surgery. Principles and Practice (, Roenigk RK, Roenigk HH Jr, eds), 2nd edn. New York, NY: Marcel Dekker, 1996; 729-39.
29. Bayrat A, McGrouther DA, Ferguson MWJ,. Skin scarring. BMJ 2003; 326: 88-92. (Pubitemid 36092292)
30. Westfall PH, Tobias RD, Rom D, et al. Multiple Comparisons and Multiple Tests Using SAS. Cary, NC: SAS Institute Inc., 1999.
31. Jereczek-Fossa BA, Santoro L, Alterio D, et al. Fatigue during head-and-neck radiotherapy: prospective study on 117 consecutive patients. Int J Radiat Oncol Biol Phys 2007; 68: 403-15. (Pubitemid 46694178)
32. Sartorius K, Killasli H, Heilborn J, et al. Interobserver variability of clinical scores in hidradenitis suppurativa is low. Br J Dermatol 2010; 162: 1261-8.
33. Sartorius K, Emtestam L, Jemec GB, Lapins J,. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009; 161: 831-9.
34. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-9. (Pubitemid 47300424)
35. Matusiak L, Bieniek A, Szepietowski JC,. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol (Stockh) 2009; 89: 601-3.
36. Mekkes JR, Bos JD,. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 2008; 158: 370-4.
37. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-94. (Pubitemid 33022088)